Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX005 and IVIg in Guillain Barré Syndrome
NCT04035135Phase 1Completed
- Sponsor
- Annexon Biosciences
- Start
- Jan 2020
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of tanruprubart in Guillain-Barré syndrome (GBS), sponsored by Annexon Biosciences. Primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at 6 months. Started Jan 2020; status: completed.
02
Drugs
tanruprubart
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT04035135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04035135.